Market-Moving News for June 24th
Portfolio Pulse from ryanfaloona@benzinga.com
Market-Moving News for June 24th: Alnylam Pharmaceuticals (ALNY) shares rise 14% after positive Phase 3 study results for vutrisiran. Altimmune (ALT) shares increase 20% following Phase 2 trial data presentation for pemvidutide. Regulus Therapeutics (RGLS) shares surge 41% after positive Phase 1b study results for RGLS8429.
June 24, 2024 | 12:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alnylam Pharmaceuticals shares are trading higher after the company announced topline results from its HELIOS-B Phase 3 study of vutrisiran, meeting primary endpoints and showing significant improvements across all secondary endpoints.
The positive Phase 3 results for vutrisiran, meeting both primary and secondary endpoints, are likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Altimmune shares are trading higher after the company presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide at the American Diabetes Association's 84th Scientific Sessions.
The presentation of positive Phase 2 trial data for pemvidutide at a major scientific conference is likely to increase investor interest and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100
POSITIVE IMPACT
Regulus Therapeutics shares are trading higher after the company announced topline results from the third cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.
The positive topline results from the Phase 1b study of RGLS8429 for ADPKD are highly significant and likely to drive substantial investor interest, leading to a sharp increase in the stock price.
CONFIDENCE 95
IMPORTANCE 95
RELEVANCE 100